Motoneurons require neurotrophic factors for their survival and their differentiation. Xaliproden (SR57746A) is a synthetic compound that exhibits ill vivo and ill vitro neurotrophic effects in several experimental studies. Here we demonstrate that neuroprotective effects of Xaliproden on motoneuron cultures are mediated by the activation of the mitogen activated protein kinase pathway. It is inhibited by PD98059, a selective and irreversible inhibitor of MEKI. The activation of this pathway seems to involve two different proteins, the protein kinase C and the Ras. Indeed, we show that Xaliproden is able to activate the MAP kinases ERK1I2 and PKC in motoneurons. In addition, the use of a 5-hydroxytryptamine lA receptor antagonist, Pindobind and pertussis toxin, inhibits the effect of Xaliproden on motoneuron survival, suggesting the involvement of this G-protein coupled receptor. Morever, 8-0H-DPAT, an agonist of 5-hydroxytryptamine lA receptor, increases the survival of mouse motoneurons but not by the same extent as BDNF or xaliproden. Since 8-0H-DPAT does not act synergistically with Xaliproden, it is likely that their neuroprotective properties involve a similar pathway. Taken together, these results indicate that neuroprotective effects of Xaliproden on mouse motoneurons are dependent on the mitogen-activated protein kinase activation via 5-hydroxytryptamine lA receptor.
Motoneurons require neurotrophic factors for their survival and their differentiation. Xaliproden (SR57746A) is a synthetic compound that exhibits ill vivo and ill vitro neurotrophic effects in several experimental studies. Here we demonstrate that neuroprotective effects of Xaliproden on motoneuron cultures are mediated by the activation of the mitogen activated protein kinase pathway. It is inhibited by PD98059, a selective and irreversible inhibitor of MEKI. The activation of this pathway seems to involve two different proteins, the protein kinase C and the Ras. Indeed, we show that Xaliproden is able to activate the MAP kinases ERK1I2 and PKC in motoneurons. In addition, the use of a 5-hydroxytryptamine lA receptor antagonist, Pindobind and pertussis toxin, inhibits the effect of Xaliproden on motoneuron survival, suggesting the involvement of this G-protein coupled receptor. Morever, 8-0H-DPAT, an agonist of 5-hydroxytryptamine lA receptor, increases the survival of mouse motoneurons but not by the same extent as BDNF or xaliproden. Since 8-0H-DPAT does not act synergistically with Xaliproden, it is likely that their neuroprotective properties involve a similar pathway. Taken together, these results indicate that neuroprotective effects of Xaliproden on mouse motoneurons are dependent on the mitogen-activated protein kinase activation via 5-hydroxytryptamine lA receptor.
Xaliproden or SR57746A {1-[2-(naphth-2yl)ethyl]-4-(-trifluoromethylphenyl) I, 2, 5, 6tetra-hydropyridine hydrochloride} was reported as an orally active compound which is able to cross the blood-brain barrier and exhibits in vivo and in vitro neurotrophic effects in several experimental models. In vivo, it prevents the decrease ofcholine acetyltransferase and acety lchol inesterase acti vi ties in a model of neurodegenerati ve disease in rats (I). Moreover, it has been shown that Xaliproden increases the mean survival time and the motor performances ofpmn (progressive motor neuronopathy) mice (2), a strain which displays an inherited axonopathy resembling Charcot Marie Tooth type II disease (3) . In vitro, it potentiates the promoting effect of nerve growth factor (NGF) on neurite outgrowth of PC 12 cells (4-5) and attenuates the cytostatic-induced reduction of neurites outgrowth in cocultures of Rat dorsal root ganglia and Schwann cells (6) . Furthermore, Xaliproden increases the phenotopic survival of embryonic purified mouse motoneurons in vitro to the same extent as brain-derived neurotrophic factor (BDNF). It also increases the outgrowth and number of their neurites (7) . The molecular mechanisms of action ofXaliproden remain poorly understood. Some studies have reported that tyrosine kinase inhibitors could mimic the effects of this compound in PC 12 cells (5) and in motoneurons (7) .
Screening studies have shown that Xaliproden has high affinity for 5-hydroxytryptaminergic 5-HT1i\receptors (4, 8, 9) . These receptors are coupled, via specific G /G o proteins, to inhibitory pathways (inhibition of adenyl cyclase (AC) activity and regulation of ion channels), and also stimulate phospholipase C (PLC) and the mitogen-activated protein kinase (MAPK) (10) . Recently, it has been shown that 5-HT 1i\ receptors are coupled to MAPK activation via f3"Y subunit of G protein (Gf3"Y) and a multi molecular cascade involving Src-like proteins, phosphatidylinositoI3-kinase, Shc-Grb2-Sos complex (11-12) and a phosphatidylcholinespecific PLC (13) . Furthermore, MAPK can mediate functional activities independently from the ex subunit of G protein-mediated adenylcyclase axis. In many cellular systems, activation ofMAPK pathway by trophic factors has been reported to be involved in the regulation of gene transcription (14) as well as proliferation and differentiation (15) . The extracellular signal-regulated protein kinases ERKI and ERK2 are members of the MAPK family. Activation of ERK is usually considered as the terminus of a linear signalling cascade involving growth factor receptors, SH2/ SH3 adapter proteins, guanine nuc leotide exchange factors, p21 Ras, Raf-I and MAPK-activating kinases such as MAPK kinase (MEK). However, there are emerging data indicating that signalling proteins such as phosphatidylinositol-j-kinase (PI3K) and protein kinase C (PKC) can also phosphorylate MEK and ERK independently from the p21 Ras pathway (16) (17) .
Here we demonstrate that Xal iproden acti vates ERK via a pertussis toxin-sensitive mechanism involving the 5-HT 1i\ receptors, the guanine nucleotide exchange factor p21 Ras, PKC and the MAPK kinase, MEK-I . Furthermore, Gvproteinstimulated ERK activity appears to be essential for the survi val effect of Xal iproden on embryonic purified mouse motoneurons in vitro.
MATERIALS AND METHODS

Drugs
Xaliproden (Sanofi-Synthelabo Recherche, Montpellier, France) (Mol wt 417.90) was dissolved in dimethyl sulfoxide (DMSO; Sigma, L'isle d'Abeau, France), and used at a final concentration of I u.M. Human brain-derived neurotrophic factor (BDNF; Tebu, Le Perray-en-yvelines, France) was used at a final concentrations-of 50 ng/ml. PD98059 (2-Amino-3methoxyflavone, Calbiochem, Darmstadt, Germany), 
Mouse motoneuron cultures
Mouse purified motoneurons were isolated as previously described by Duong et al (7) . Briefly, spinal cord of E 13-E 14 Swiss mouse embryos were dissected and incubated for 20 min. at room temperature in 0.025% (weight/volume) isotonic trypsin solution (LPCR, Schiltigheim, France). After several mechanical dissociations and purifications, cells were seeded in 24-well plates (N alge Nunc, Polylabo, JIIkirch, France), precoated for 3 h with a 0.3 mg ml' aqueous solution of poly-L-Iysine (Sigma) and were maintained in a defined medium and cultured at 37°C in a humidified (95%)-CO 2 (5%) atmosphere. Motoneurons express islet-I transcription factor (18) and this property allows it to distinguish them from other spinal cells which do not express this transcription factor. It is therefore possible to identify motoneurons by immunolabelling with an anti-Islet-I antibody. The purity ofa culture was assessed by determining the percentage of immunolabelled cells using a phase contrast microscope. More than 90 % of cells were positive for Islet-I. Cells were treated immediately after seeding. All the wells contained DMSO at a final concentration of 0.02%. Sixty percent of the medium was replaced every 2 days with fresh medium.
Cell counting
Motoneurons were counted 2h after sccdi ng and then 96 h. later under a phase microscope. Five random fields per well were used. Resul ts are expressed as a ratio ofpercentages (percentage of survi ving motoneurons in treated cultures/percentage of surviving motoneurons in control cultures). Each experimental condition was tested in dupl icate and experiments were repeated three times.
Double labeling immunocytochemistry and confocal laser scanning microscopy
Motoneurons were grown on poly-lysine coated glass coverslips for 24 h. Cells were then rinsed with PBS (phosphate-buffered solution), and subsequently fixed with 4% (w/v) para formaldehyde at 4°C. Following 3 rinses at 37°C, cells were incubated with serum albumin 3% (w/v) in PBS at room temperature for 30 m to reduce non specific binding. Coverslips were then incubated at room temperature for 2 h with primary antibody: Islet-I antibody (Chemicon International, Temecula, CA, USA) or 5-HTI A antibody (Chemicon International). After 3 washes, cells were incubated for I h at room temperature with cyanin 3 (CY3)-labeled anti-rabbit antibody (Sigma) or Fluorescein-conjugated anti-guinea pig (Chemicon International). After extensive washing, the coverslips were mounted in 50% glycerol/ 50% water. Immunofluorescence staining was monitored with a Zeiss laser scanning microscope (LSM 510) equipped with a Pan-Achromat 63x oil immersion lens.
Preparation of total cell extracts
After incubation under different experimental conditions, cells were washed twice with icc-cold PBS and harvested in lysis buffer (20 mM Tris pH 8, 137 mM sodium chloride, 1% Nonidet P-40, 10% glycerol, 50mM sodium fluoride, I OmM sodium pyrophosphate) supplemented with leupeptin (5 ug/ml), anti pain (5Ilg/ ml), chymostatin (5Ilg/ml), aprotinin (5Ilg/ml), E64 (I mgll) and sodium orthovanadate (5 mM) (Sigma). Cell Iysates were cleared by centrifugation at 16,000 x g for 10 min. The proteins in total Iysates were assayed before immunoprecipitation or polyacrylamide gel electrophoresis (PAGE). Measurements were done using a micro BCA kit (Pierce, Rockland, IL, USA) with BSA as a standard.
Immunoblotting
An aliquot of protein (15Ilg) was applied to a 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). After being transferred onto nitrocellulose membrane (Amersham), blots were blocked with a 3% BSA (bovine serum albumin) solution and then incubated with the anti-ACTIVE MAP kinase (Prom ega Corporation, Madison, WI, USA) or antiphospho PKC (New England Biolabs, Beverly, MA, USA) antibodies. The blots were washed three times in TBST (tris-buffered solution with 0,05% of tween) and were incubated with peroxidase-labeled anti-rabbit Ig antibody (Amersham, ECL kit). The bands were visualized using ECL Western blotting detection kit by exposure to X-ray films (RPN2l 03H from Amersham). To reprobe the blots, the membrane was stripped for 15 m in Restore Western Blot buffer (Pierce) blocked, and reprobed with anti-actin antibody (Sigma).
Stastistical analysis
Differences between treated and control cultures were evaluated using a one way analysis of variance (ANOVA) test followed by a Fisher test for multiple comparisons. All statistical analyses were performed using Statview Student software (Abacus Concepts Inc., Berkeley, CA, USA).
RESULTS
Involvement ofERK1/2 kinases on xaliprodeninduced motoneurons survival
Under our experimental conditions, BDNF (50 ng.ml') and Xaliproden (1 I-LM) significantly increase the percentage of phenotypic surviving motoneurons, as compared with control cultures. These results are in agreement with those reported in previous studies (7) .
It has been demonstrated that PD98059 inhibits the activation of MEK I in response to growth factors and prevents the activation of MAP kinases in various cells (19) (20) . In our studies, PD98059 (10 I-LM) significantly inhibits the effects of Xaliproden or BDNF on motoneuron survival (P<0.05; Xaliproden or BDNF-and PD98059treated cultures versus Xal iproden or BDNF-treated cultures) ( Fig. I) . PD98059 alone did not modify the survival time of motoneurons (the ratio is zx: I). These data suggest that the effect of Xaliproden on motoneuron survival is mediated by MEK I in the same order as the one of BDNF. To confirm that ERKII2 are activated in response to the stimulation by BDNF and Xaliproden, Iysates from motoneurons were treated for 10 min., 60 min. or 360 min. and then their content in phosphorylated ERK 1/2 was checked. Fig. 2 shows that the phosphorylation of ERK 1/2 was already detectable after 10 min. of treatment with BDNF. and after 60 min. of treatment with Xaliproden . After 360 min. , activ ation of ERK 1/ 2 by Xaliproden decreases (da ta not show n) .
Involvement of Ras in the effect of Xalip rode n on ph enotypic moton euron surv ival
Ras is acti vated by a gre at variety ofextracellular stimuli, including gro wth fact ors and hormones. Act ivated Ra s could initiate MEK acti vation. This is the motivation behind thi s study of the effect of FPT inhibitor I, a potent and sele ctive inhibitor of Ras farnesylation (21) on the neuroprotecti ve effects of Xaliproden.
FPT inhibitor I alone ha s no effect on the survival time ofmotoneu rons as illustrated in fig .  3a . In combination with X aliproden (I I-LM), FPT inhibitor I ( I jJ.M ) does not inhib it significantly th e effec t ofXaliproden on mot oneurons (p> 0. 05; Xal iproden-and FPT inh ib itor I-treat ed culture s versus Xaliproden-treated cultures) . On the contrar y, FPT-I inhibits th e BDNF-induced motoneuron surv ival (p<O.OI; BDNF-and FPT inhibitor Itre ated cultures vers us BD NF-treated cultures) ( Fig . 3a ) .
Protein kina s e C is in vol v ed in th e neuroprotec tive ef fec ts of Xa liprode n
Since MEK is located do wn stream of PKC, we have attempted to determ ine w hether thi s pathway is implicated in the effect of Xaliproden on motoneuron surviv al.
For this purpose, we used two selective inhibitors ofPKC, GFt 09203X and Chelerythrine. GF I09203X binds to the cat al yti c domain of PKC (22) . Chelerythrine interact s with the catalytic domain of PKC and selective ly inhibits PKC (23) . Fig . 3a shows that GF10920 3X al o ne (l I-LM) do not modify the s urv iva l of motoneuron s but combined w ith Xaliproden ( I I-LM ), could weaken the effect of Xaliproden on the surv iv al time of these ce lls, but not significantly. Thi s result sug ge sts that PKC could be partiall y in vol ved in the mech ani sm of action of Xaliproden . On the other hand, BDNF effect on motoneuron surv iv al is not mod ified by GFI09203 X (Fig. 3a) .
Considering that the effect o f Xaliproden is not completely aboli sh ed either by FPT inhibitor I or by GFI09203X, we co mbined these two inhibitors to determine whether they had additive effect on the survival of motoneurons. As shown in Moreover, fig. 4 demon str ates that Xaliproden is abl e to phosphorylate PKC afte r 10 min. of in cubati on. PKC phosphoryl ati on is required for 
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its activation (24) . This phosphorylation (activation) remains sustained during 360 min. and then decreases (data not shown).
Involvement of 5-HT JA receptors in the effect of Xalip roden
5-HT 1A receptor has been reported to activate various enzymes and kinases such as adenylate cyclase (AC), PKC and Ras. This activation has been shown to be sensitive to pertussis toxin, which suggests that G ilo proteins are involved in the signalling cascade triggered by 5-HT 1A receptor.
To determine whether 5-HT 1A receptors are involved in the neuroprotective effect ofXaliproden on motoneuron survival, we used Pindobind, an antagonist of 5-HT 1A receptor (25) , and pertussis toxin. Pertussis toxin is known to inhibit specifically G j and/or Goby ADP-ribosylation of the a-subunits of the G-proteins (26) . with Xaliproden (l/LM), it significantly decreases the effect of Xaliproden on motoneuron survival ( Fig. 5 ) (P<O.OO 1, pertussis toxin-and Xaliprodentreated cultures versus Xaliproden-treated cultures). The BDNF effect on motoneuron survival is not modified either by pindobind or by pertussis toxin (Fig. 5) . These data suggest that the neuroprotective effect ofXaliproden on motoneuron survival results from 5-HT'A receptor activation.
To confirm this hypothesis, we used an agonist of 5-HT'A receptor, 8-0H-DPAT, to check its ability to protect motoneurons in culture. Fig. 6 shows that 8-0H-DPAT (500 nM and 1 /LM) significantly increases the percentage of surviving cells, in a dose-dependant manner, but not as well as BDNF (50 ng/ml) or Xaliproden (1 /LM). At a dose of up to 1 /LM, 8-0H-DPAT is harmful for motoneurons. When used in combination with Xaliproden (1/LM), 8-0H-DPAT (500 nM and 1 /LM) is not more efficient than when used alone (data not shown). We therefore conclude that both neuroprotective agents do not act in an additive or synergistic manner.
The presence of 5-HT 1A receptors on motoneurons was verified by a double immunocytochemical labeling against Islet-l , a specific transcription factor of motoneurons, and 5-HTlA receptors (Fig. 7) .
DISCUSSION
The present results show that neuroprotective effects of Xaliproden are sensitive to various inhibitors such as PD98059 (MEKI inhibitor), FPT-I inhibitor (Ras inhibitor), GFl09203X and Chelerythrine (PKC inhibitors). They are also sensitive to Pindobind and pertussis toxin, both deactivating 5-HT 1A receptors. Moreover, Xaliproden activates both ERK 1/2 and PKC. Taken together, these data indicate that Xaliproden could exert its neuroprotective effect by activating MAPK via the Ras-ERK pathway and partly through 5-HT'A receptor activation.
5-HT 1A receptor activates several protein kinases. These include serine-threonine, tyrosine, and lipidkinases (27) . For instance, 5-HT 1A receptor can activate PKC via PLC (28) . Activation ofPKC through 5-HT 1A receptor depends upon PLC activation. Since this effect is probably mediated by G-protein l3a-subunits, it depends on the expression of 13)'-regulated PLC in the target cell or tissue.
It has been shown that 5-HTlA receptor activates ERK and MAPK in CHO cells (11) (12) (13) (29) (30) (31) . Such stimulation has been reported to inhibit apoptosis in neuronal cells (32) (33) . Moreover, another set ofMAPK, namely c-jun kinase (JNK) and p38, and the nuclear factor HNFKB are also activated in response to extracellular stimuli, via Ras and Raf-l, leading to the death of the cells (33) . Considering these findings, it has been proposed that extracellular signals could induce a switch from the cell death-causing Ras-Raf-lstress-activated kinase (SEK)-JNK or Ras-Raf-l-SEK-HNFKB pathway to the protective Ras-Rafl-MEK-ERK pathway (33) . This means that a selective inhibition of the ERK pathway would eliminate its protective effect on cell survival. We observe here that a selective inhibitor ofthe MEK-ERK pathway (PD98059) blocked Xaliproden neuroprotective effects on purified mouse motoneuron cultures, which supports the interpretation mentioned above.
Adayev et al. (32) have shown that the 8-0H-DPAT-mediated protection of neuronal HN2-5 cells resulted from a stimulation of the Ras-Raf-l-MEK-ERK pathway probably through PLCI3 activation. We report here that neuroprotective effects of Xaliproden could be attributable to a stimulation of the PKC-MEK-ERK pathway as well as the Ras-Raf-l-MEK-ERK pathway. Furthermore, we have shown that 8-0H-DPAT and Xaliprodendo not act in an additive or synergistic manner. These observations suggest that both agents could partly act through a common, parallel or branched pathway. Nevertheless, the 8-0H-DPAT effect on the motoneuronal survival is different from that of Xaliproden. This suggests that Xaliproden also could have intracellular targets. Indeed, several studies have shown that 5-HTlA agonists are unable to have the same neuroprotective and neurotrophic effects of Xaliproden in vitro and in vivo (4) . Furthermore, studies in vivo of several derivates ofXaliproden, with high affinities for the 5-HTlA receptor, have shown that they do not have the same effects than those of Xaliproden (34) .
Summarizing, Xaliproden could increase phenotypic motoneuron survival by activating the MAPK pathwaypartly dependent on 5-HT IA receptor stimulation. Further studies should be carried out to identify the proteins susceptible to connect 5-HT 1A receptor activation and the PKC/Ras-Raf-I-MEK-ERK pathway to the anti-apoptotic effect of Xaliproden.
